CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Blood

Volumn 126, Issue 6, 2015, Pages 779-789

  Hagner, Patrick R ^a   Man, Hon Wah ^a   Fontanillo, Celia ^a   Wang, Maria ^a   Couto, Suzana ^a   Breider, Mike ^a   Bjorklund, Chad ^a   Havens, Courtney G ^a   Lu, Gang ^a   Rychak, Emily ^a   Raymon, Heather ^a   Narla, Rama Krishna ^a   Barnes, Leo ^a   Khambatta, Gody ^a   Chiu, Hsiling ^a   Kosek, Jolanta ^a   Kang, Jian ^a   Amantangelo, Michael D ^a   Waldman, Michelle ^a   Lopez Girona, Antonia ^a   Cai, Ti ^a   Pourdehnad, Michael ^a   Trotter, Matthew ^a   Daniel, Thomas O ^a   Schafer, Peter H ^a   Klippel, Anke ^a   Thakurta, Anjan ^a   Chopra, Rajesh ^a   Gandhi, Anita K ^a   more..

^a CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; CC 122; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 2; RETINOIC ACID INDUCIBLE PROTEIN I; UNCLASSIFIED DRUG; 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE; CRBN PROTEIN, HUMAN; IKAROS TRANSCRIPTION FACTOR; IKZF1 PROTEIN, HUMAN; IKZF3 PROTEIN, HUMAN; INTERFERON; IRF7 PROTEIN, HUMAN; LENALIDOMIDE; PEPTIDE HYDROLASE; PIPERIDONE DERIVATIVE; POMALIDOMIDE; QUINAZOLINONE DERIVATIVE; SMALL INTERFERING RNA; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LARGE CELL LYMPHOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; B LYMPHOCYTE; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LENTIVIRINAE; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MOLECULAR MIMICRY; MOUSE; PATHOLOGY; SCID MOUSE; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IKAROS TRANSCRIPTION FACTOR; INTERFERON REGULATORY FACTOR-7; INTERFERONS; LENTIVIRUS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, SCID; MOLECULAR MIMICRY; PEPTIDE HYDROLASES; PIPERIDONES; PROTEOLYSIS; QUINAZOLINONES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; THALIDOMIDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940063236     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-628669     Document Type: Article

References (36)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780-2795.
2. Vaidya R, Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol. 2014;25(11):2124-2133.
3. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-4126.
4. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511.
5. Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123(8):1214-1217.
6. Lenz G, Wright G, Dave SS, et al Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
7. Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29(31):4079-4087.
8. Gangatharan S, Kuruvilla J. Relapsed and refractory aggressive NHL: time for a change. Transfus Apher Sci. 2013;49(1):72-79.
9. Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21(9):803-809.
10. Fischer ES, Böhm K, Lydeard JR, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512(7512):49-53.
11. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305-309.
12. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301-305.
13. Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164(6):811-821.
14. Rasco DW, Gandhi AK, James A, et al. A first in human dose escalation study of CC-122, a first-in-class pleiotropic pathway modulator™ (PPM) compound in subjects with relapsed or refractory solid tumors, multiple myeloma and non-Hodgkin's lymphoma [abstract]. Blood. 2013;122(21). Abstract 2905.
15. Ribrag V, Damian S, Gharibo M, et al. CC-122 degrades the lymphoid transcription factor Aiolos (IKZF3) by modulating Cereblon and shows clinical activity in a phase Ib study of subjects with relapsed or refractory non-Hodgkin's lymphoma and multiple myeloma [abstract]. Blood. 2014;124(21). Abstract 3500.
16. Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160(4):487-502.
17. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell. 2010;38(1):114-127.
18. Wang J, Gu Q, Li M, et al. Identification of XAF1 as a novel cell cycle regulator through modulating G(2)/M checkpoint and interaction with checkpoint kinase 1 in gastrointestinal cancer. Carcinogenesis. 2009;30(9):1507-1516.
19. Rosebeck S, Leaman DW. Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a. Apoptosis. 2008;13(4):562-572.
20. Zhang J, Jackson AF, Naito T, et al. Harnessing of the nucleosome-remodeling-deacetylase complex controls lymphocyte development and prevents leukemogenesis. Nat Immunol. 2012;13(1):86-94.
21. Bandyopadhyay S, Montagna C, Macian F. Silencing of the Il2 gene transcription is regulated by epigenetic changes in anergic T cells. Eur J Immunol. 2012;42(9):2471-2483.
22. Koipally J, Georgopoulos K. Ikaros-CtIP interactions do not require C-terminal binding protein and participate in a deacetylase-independent mode of repression. J Biol Chem. 2002;277(26):23143-23149.
23. Havens C, Bjorklund C, Kang J, et al. IMiDs® immunomodulatory agents regulate interferon-stimulated genes through cereblon-mediated Aiolos destruction in multiple myeloma (MM) cells: identification of a novel mechanism of action and pathway for resistance [abstract]. Blood. 2014;124(21). Abstract 3432.
24. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622-1627.
25. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(30):4952-4957.
26. Czuczman M, Davies A, Linton K, et al. A phase 2/3 multicenter, randomized study comparing the efficacy and safety of lenalidomide versus investigator's choice in relapsed/refractory DLBCL [abstract]. Blood. 2014;124(21). Abstract 628.
27. Quintana FJ, Jin H, Burns EJ, et al. Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat Immunol. 2012;13(8):770-777.
28. Yoshida T, Ng SY, Zuniga-Pflucker JC, Georgopoulos K. Early hematopoietic lineage restrictions directed by Ikaros. Nat Immunol. 2006;7(4):382-391.
29. Ng SY, Yoshida T, Zhang J, Georgopoulos K. Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. Immunity. 2009;30(4):493-507.
30. Yang Y, Shaffer AL III, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6):723-737.
31. Farrugia MM, Duan LJ, Reis MD, Ngan BY, Berinstein NL. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes. Blood. 1994;83(1):191-198.
32. Perry AM, Alvarado-Bernal Y, Laurini JA, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol. 2014;165(3):382-391.
33. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360-3365.
34. Ma S, Pathak S, Mandal M, Trinh L, Clark MR, Lu R. Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Mol Cell Biol. 2010;30(17):4149-4158.
35. Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood. 2004;103(11):4251-4258.
36. Foon KA, Sherwin SA, Abrams PG, et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med. 1984;311(18):1148-1152.